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Abstract
Fragile X syndrome (FXS) is caused by an expanded CGG repeat (> 200 repeats) in the 5’ untranslated portion of
the fragile mental retardation 1 gene (FMR1), leading to deficiency or absence of the FMR1 protein (FMRP). FMRP is
an RNA carrier protein that controls the translation of several other genes that regulate synaptic development and
plasticity. Autism occurs in approximately 30% of FXS cases, and pervasive developmental disorder, not otherwise
specified (PDD-NOS) occurs in an additional 30% of cases. Premutation repeat expansions (55 to 200 CGG repeats)
may also give rise to autism spectrum disorders (ASD), including both autism and PDD-NOS, through a different
molecular mechanism that involves a direct toxic effect of the expanded CGG repeat FMR1 mRNA. RNA toxicity can
also lead to aging effects including tremor, ataxia and cognitive decline, termed fragile X-associated tremor ataxia
syndrome (FXTAS), in premutation carriers in late life. In studies of mice bearing premutation expansions, there is
evidence of early postnatal neuronal cell toxicity, presenting as reduced cell longevity, decreased dendritic arboriza-
tion and altered synaptic morphology. There is also evidence of mitochondrial dysfunction in premutation carriers.
Many of the problems with cellular dysregulation in both premutation and full mutation neurons also parallel the
cellular abnormalities that have been documented in autism without fragile X mutations. Research regarding dysre-
gulation of neurotransmitter systems in FXS, including the metabotropic glutamate receptor (mGluR)1/5 pathway
and g aminobutyric acid (GABA)A pathways, have led to new targeted treatments for FXS. Preliminary evidence
suggests that these new targeted treatments will also be beneficial in non-fragile X forms of autism.
Introduction
Fragile X syndrome (FXS) is an important subtype of
autism, both because of its frequency and because
knowledge of the molecular mechanisms involved in its
pathogenesis has facilitated the development of targeted
treatments with the potential to reverse or dramatically
improve both behavioral and cognitive deficits. Because
FXS is the most common single gene cause of autism,
responsible for 2% to 6% of all cases of autism, it is
clinically recommended that all individuals diagnosed
with autism or ASD should have the FX DNA test (both
PCR and Southern blot) when the etiology of their
autism is not known [1-4]. FXS is nearly always caused
by a trinucleotide (CGG) repeat expansion, located in
the 5’ untranslated region of the FMR1 gene, to a length
of greater than 200 repeats (full mutation range). Full
mutation expansions typically lead to methylation of the
gene, reduced or absent transcription, and consequent
decreased reduction in translation of the FMR1 protein
(FMRP), the proximal basis of FXS. FMRP levels are
correlated with the degree of clinical involvement
including physical, cognitive and structural/functional
brain involvement [5-10].
Approximately 30% of males with FXS have full autism,
as determined by the standardized criteria of the Autism
Diagnostic Observation Scale (ADOS) and the Autism
Diagnostic Interview (ADI-R) [11-15]. An additional 30%
of boys have pervasive developmental disorder, not other-
wise specified (PDD-NOS) [11]. Among the remaining
patients with FXS, of those who do not meet the criteria
for an autism spectrum disorder (ASD) diagnosis, the
majority have one or more autistic features, such as hand
flapping, poor eye contact and tactile defensiveness [11].
A premutation CGG-repeat range (55 to 200 repeats)
was initially defined in terms of an increased frequency
of expansion of the CGG repeat to the full mutation
range when transmitted by a premutation (carrier)
woman. All children with the full mutation have a
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tation could have received this mutation from either her
mother or her father. Moreover, the propensity for
transmission of a full mutation allele increases with
increasing CGG repeat number in the mother [16].
A father who is a carrier of either a premutation or full
mutation allele will pass only a premutation to all of his
daughters, presumably due to selective production of
premutation allele-bearing sperm [17].
Carriers of premutation alleles were generally consid-
ered to be clinically uninvolved until premature ovarian
failure, recently renamed FX-associated primary ovarian
insufficiency (FXPOI), was reported [18]. Subsequently,
the late onset neurodegenerative disorder, FX-associated
tremor ataxia syndrome (FXTAS), was described [19,20],
further establishing clinical involvement among premu-
tation carriers. It is now evident that a spectrum of neu-
rodevelopmental and aging/neurological problems are
associated with premutations, including autism and ASD
[21-26]. Most individuals with a premutation are neither
developmentally disabled nor do they have autism; how-
ever, a subgroup does experience cognitive, emotional
and/or behavioral involvement. There is a negative
correlation between CGG repeat number and the level
of FMRP in a premutation range [27], which predisposes
individuals in the high end of a premutation range to
cognitive and behavioral impairment. In addition, all
individuals with a premutation have elevated FMR1
mRNA, whereas the opposite occurs in the full mutation
[27]. Thus, the cognitive and behavioral impairments in
a premutation and full mutation ranges are likely to
have both distinct and overlapping mechanisms.
Clinical and molecular involvement in FXS, and
association with autism
The basis for incomplete penetrance of autism (30%) or
PDD-NOS (30%) among individuals with FXS is not
known. However, there is evidence that patients with
additional medical disorders that affect the CNS, such
as seizures or additional genetic problems, have an
increased risk for autism compared with patients with
FXS alone [28-30]. For those with both FXS and autism,
there is a spectrum of involvement with significant
heterogeneity, both cognitively and behaviorally, with IQ
values ranging from severely intellectually impaired to
normal, particularly in females. However, there is a
strong association between low IQ and the autism diag-
nosis in both males and females with FXS [11-14,31-35].
The cause of this heterogeneity is related to background
genetic effects and environmental effects that influence
IQ, social abilities, anxiety, attention deficit hyperactive
disorder and additional features that are components of
the FXS phenotype (Figure 1). Background genetic
effects include additional pathological mutations (FXS
has been reported with sex chromosome disorders,
Down syndrome, Tourette syndrome and other condi-
tions [28,29,36], allelic variants [37], and gene expres-
sion changes [38]). An example of the later condition is
the Prader-Willi phenotype (PWP) of FXS, in which
there is no structural or methylation change at 15q
11-13; rather, there is significant downregulation of
expression of CYFIP 1, which is located at the 15q locus
in Prader-Willi syndrome (PWS) [38]. Males with the
PWP of FXS have severe obesity, hyperphagia and hypo-
genitalia, and a higher rate of ASD than those with FXS
without the PWP [38].
Environmental influences on the phenotype of FXS
include exposures to toxins (for example, alcohol, lead-
ing to fetal alcohol syndrome and FXS), abuse (physical
or sexual), neglect, perinatal asphyxia, head trauma,
seizures and socioeconomic status. Additional environ-
mental exposures leading to further toxicity are just
beginning to be explored in both premutation and full
mutation involvement, as they are in idiopathic autism
[39-42]. Such studies are occurring at a cellular level in
premutation neurons; these neurons die earlier than do
control neurons, with increased cell death documented
by 21 days in culture [43]. In addition, mitochondrial
dysfunction has been documented in fibroblasts and
brain tissue in premutation carriers both with and with-
out FXTAS [44]. We hypothesize that premutation
neurons are more vulnerable to environmental toxins,
and clinical case reports appear to support this notion
[42,45].
The absence of FMRP in individuals with FXS has sig-
nificant consequences in the translation of dozens and
probably hundreds of proteins. Because FMRP usually
suppresses translation, its absence leads to broad trans-
lational upregulation in the hippocampus [46]. Recent
studies by Darnell et al. [47] and others have demon-
strated linkage between FMRP and many proteins
that are related to autism, including neuroligin 3 and 4,
neurorexin, PDP (postsynaptic density protein) 95,
CYFIP (cytoplasmic FMR1 interacting protein) 1 and 2,
SHANK (Src homology 3 and multiple ankyrin repeat
domains)3, Arc, PTEN (phosphatase and tensin homo-
log), MAPK (mitogen activated protein kinase), JAKMIP
(janus kinase and microtubule interacting protein)1 and
HERC (homologous to the E6-AP carboxyl terminus)
and regulator of chromosome condensation (RCC)1-like
domain-containing protein) 2, among others [2,4-50].
Most of these proteins are associated with synapse for-
mation and plasticity; however, the PTEN gene encodes
a dual specificity phosphatase effecting G1 cell cycle
arrest and/or apoptosis, and 17% (3/18) of individuals
with autism and macrocephaly were found to have a
PTEN mutation [51]. Macrocephaly also occurs in FXS,
often with a broad forehead remarkably similar to the
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characteristic is hypothesized to be related to the down-
regulation of PTEN that occurs in FXS [47,52]. Expres-
sion of JAKMIP1 and the G protein coupled receptor
(GRP)155 were both altered by reduction of FMRP
(seen in FXS) or induction ofC Y F I P 1( s e e ni nt h e1 5 q
duplication form of autism) in vitro [53]. These proteins
were also dysregulated in boys with idiopathic ASD rela-
tive to their unaffected siblings [53]. Both CYFIP1
(a partner protein to FMRP and regulated by FMRP)
and JAKMIP1 are involved with the RacGTPase system,
which modulates the neurite development that is crucial
for proper brain connectivity [54]. There is also evidence
for upregulation of the mammalian target of rapamycin
(mTOR) pathway in the hippocampus of the knockout
(KO)mouse [55] and in studies of humans with FXS
[56]. The mTOR pathway is dysregulated in several
other genetic disorders that are associated with autism,
such as tuberous sclerosis (TS) [57]. These findings have
stimulated targeted treatments using rapamycin to
downregulate the mTOR system in patients with TS,
with initially positive results. The overlap of molecular
mechanisms in those with a premutation or the full
mutation and idiopathic autism is shown in Figure 2.
Recently, a number of studies have directly compared
patients with FXS and those with autism without FXS.
There are unique structural differences in the central ner-
vous system (CNS) between the two disorders even when
both disorders have comparable degrees of autism as
assessed by standardized behavioral measures [58]. Those
with FXS have an enlarged caudate compared with typi-
cally developing individuals and those with autism,
whereas those with autism have a larger amygdala com-
pared with FXS or controls [58]. These differences con-
t i n u et oe v o l v ew i t ha g e ,a sd o e st h es e v e r i t yo ft h e
autistic features in FXS [59]. Therefore, from early in life,
and probably in utero, there are structural CNS changes
that are related to the lack of FMRP. The dysregulation
Figure 1 Overview of the behavioral/cognitive phenotype of fragile X syndrome (FXS). The interrelationships among cognitive, behavioral
and attentional deficits in FXS are modified by additional environmental influences and genetic background effects. Environmental influences
include seizures, trauma, abuse and socioeconomic status. Genetic influences include allelic variations, additional genetic disorders and variation
in the expression levels of genes important for the phenotype of FXS.
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connectivity in the brain leads to the gradual deficits in
socialization, behavior and cognition that characterize the
FXS phenotype [60,61]. Although eye contact problems
are usually not present during the first year of life, they
evolve over time, as do the sensory hyperarousal, anxiety,
motor and social deficits. Hoeft et al. [62] have reported
that the early trajectory of brain growth abnormalities in
FXS becomes more exaggerated over time and includes
enhanced growth of the caudate, nucleus basalis and tha-
lamus, compared with controls. Those authors also docu-
mented enhanced white matter volume, particularly of
the striatal-frontal regions, becoming more dramatic in
the early years (1 to 3 years of age), which suggests
axonal pathology as opposed to secondary connectional
dysregulation [62]. Their work further suggests that the
earlier the intervention is begun, the better the outcome
for an individual with FXS. These findings provide neuro-
biological support for initiating interventions as early in
the lifespan as possible, although further clinical studies
are needed. A summary of treatment for FXS was
reviewed by Hagerman et al. [63].
RNA toxicity and a premutation carrier
The discovery of the neurodegenerative disorder,
FXTAS, in older adult carriers of premutation alleles,
Figure 2 Molecular overlap between autism, fragile x syndrome (FXS) and premutation disorders. Absence of the FMR1 protein (FMRP)
leads to the dysregulation of several proteins including those involved with synapse formation and plasticity, glutamate and g aminobuyric acid
(GABA) neurotransmission and mammalian target of rapamycin (mTOR) and phosphatase and tensin homolog (PTEN) pathways. A premutation is
associated with elevation of FMR1 mRNA, leading to sequestration of proteins and mitochondrial dysfunction. Many of these same molecular
changes can also occur in some types of autism. Some patients with FXS have mosaicism of premutation and full cells, so there is overlap of the
molecular mechanisms among all three disorders.
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the premutation range, led to the recognition of an
entirely distinct pathogenic mechanism associated with
the FMR1 gene: RNA toxicity [64-68]. A range of stu-
dies on the adverse consequences of expressing the
expanded CGG repeat in human, animal and cell mod-
els has helped to establish an RNA toxicity model invol-
ving a toxic gain of function of premutation FMR1 RNA
[69-79]. However, although carriers of premutation
alleles have elevated FMR1 mRNA [27,80,81], the stron-
gest argument for an RNA-based toxicity mechanism in
both FXTAS and FXPOI [82-84], is that these clinical
syndromes are limited to a premutation repeat range,
where the gene is active; that is, low levels (or absence)
of FMRP do not cause either FXTAS or FXPOI. How-
ever, moderately lowered FMRP levels in the upper pre-
mutation range may compound the effects of elevated
RNA levels (a mechanistic issue that still needs to be
resolved) but the primary effect appears to be expression
of the expanded CGG-repeat RNA. A supporting argu-
ment for an RNA-based mechanism is that the FMR1
mRNA is found within the characteristic intranuclear
neuronal and astrocytic inclusions of FXTAS [85,86].
FXTAS was originally described as a late adult-onset
neurodegenerative disorder; however, there is an emer-
ging view that FXTAS, and probably also FXPOI, is the
end stage of a process that actually begins in early
development, and that may be responsible for the emo-
tional and behavioral problems, cognitive impairment,
ASD and seizure activity experienced by children who
are carriers of premutation alleles [21,25,87]. This view
is based on a combination of animal and cell-based
studies for early abnormalities resulting from expression
of a premutation allele. In particular, Chen et al. [43]
demonstrated that in cultured hippocampal neurons
from day 1 postnatal premutation (knock-in; KI) mice,
there were CGG repeat-dependent decreases in both
the number of branches and the interbranch lengths,
and decreased longevity in culture. Moreover, Garcia-
Arocena et al. [88] observed abnormal lamin A/C archi-
tecture, with loss of ring-like nuclear staining, in
embryonic fibroblasts from the KI mouse. In behavioral
studies with the KI mice, there were progressive deficits
in spatial processing (but no motor involvement) in
mice as young as 12 weeks [70,89]. These observations,
plus elevated levels of FMR1 mRNA in children with
premutation alleles [90], support the presence of an
early developmental component of FMR1 mRNA-asso-
ciated toxicity.
Based on the toxic RNA gain of function model for
myotonic dystrophy, in which disease pathogenesis
involves the sequestration of one or more proteins by
an expanded rCUG repeat in the 3’ untranslated region
of the myotonic dystrophy protein kinase (DMPK) gene
[91,92], the first view of FXTAS envisioned a similar,
direct-RNA mechanism in which proteins would be
sequestered by the expanded CGG repeat [19,65,67,69].
A growing number of animal and cell- l-based studies
support this ‘direct RNA’ model [71,72,93,94]. Recently,
Sellier et al. [94]presented evidence for both sequestra-
tion of an RNA processing protein, Sam68 and the
consequent altered splice-site regulation of several
RNAs whose splicing is known to be regulated by
Sam68. In addition to their demonstration of the func-
tional consequences of Sam68 sequestration, Sellier
et al. demonstrated that the incorporation of the protein
into nuclear aggregates displayed a CGG-repeat cutoff
that meant aggregation only occurred for expansions
exceeding ~40 CGG repeats. More recently, Sellier et al.
[95] also reported that a consequence of this sequestra-
tion is dysregulation of microRNAs, which may be
related to the clinical problems of premutation carriers.
It should be noted that although the sequestration
model remains the most viable mechanism for RNA
toxicity, the clinical data only support the requirement
for transcription. Thus, a role for other mechanisms
such as RNA-triggered signaling or co-transcriptional
mechanisms cannot be discounted [68] (Figure 3).
Evidence for a direct RNA-based (for example, seques-
tration) model cannot exclude the possibility that
co-transcriptional RNA, or even DNA, has a role in the
pathogenesis. Entezam and Usdin [74] observed that the
DNA-repair protein ATR is recruited to CGG expan-
sions, and the fact that another DNA-repair protein,
g-H2AX[96], is found in the intranuclear FXTAS inclu-
sions [97], suggests that transcription-induced DNA
damage could also trigger the pathogenesis of premuta-
tion-associated disorders.
Recent work from the laboratory of Guilivi has demon-
strated mitochondrial dysfunction in fibroblasts and brain
samples in premutation carriers both with and without
FXTAS [44]. Mitochondrial dysfunction in carriers
included uncoupling between electron transport and
synthesis of ATP in addition to decreased levels of mito-
chondrial proteins including the ATPase b-subunit
(ATPB) from complex V, the cytochrome c oxidase subu-
nit from complex IV (CCOIV) and manganese superoxide
dismutase as part of the mitochondrial antioxidant
defense. The levels of the mitochondrial proteins corre-
lated inversely with the CGG repeat numbers in the pre-
mutation range. These protein changes increased oxidative
stress and oxidatively modified mitochondrial proteins,
and activated the unfolded protein response and phos-
phorylation of the alpha subunit of the heterotrimeric
eukaryotic translational initiation factor 2 (eIF2a), result-
ing in a decrease in protein translation. Similar types of
mitochondrial abnormalities have been seen in those with
autism without a FX mutation (Giulivi et al. unpublished
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14 of 69 patients with autism had hyperlactacidemia, and
in 5 of 11 of these patients who underwent a deltoid mus-
cle biopsy, there was a mitochondrial respiratory chain
disorder with enzyme function that was <20% of normal
mean activity, including complex I, complex IV and com-
plex V abnormalities. Weissman et al. studied 25 patients
with autism and evidence of oxidative phosphorylation
abnormalities, and found 19 with elevated lactate levels,
64% with complex I deficiency and 20% with complex III
deficiency. Two of the patients had pathological mitochon-
drial DNA mutations [99]. Other reports of mitochondrial
gene mutations in children with autism have also been
reported [100-102].
Clinical involvement of some premutation carriers
Although autism and other clinical involvement in a sub-
group of young premutation carriers was initially thought
to be only an occasional occurrence [26,103-106],
research cohorts demonstrated that approximately 14%
of boys and 5% of girls with a premutation had ASD
[107]. More recent studies demonstrated a high rate of
ASD (73%) in boys with a premutation who were referred
clinically to the UC Davis MIND Institute, although this
was much lower in premutation males who were identi-
fied by cascade testing (7%) compared with their brothers
who did not have a premutation (0%) [108]. Although
there is clearly a bias towards an ASD phenotype in those
who present clinically, a recent online family question-
naire completed by over 1200 families affected by FXS
found that 19% of 57 males with a premutation had a
diagnosis of autism, which was significantly higher than
control boys (5%). In this survey 1% of 199 females with
a premutation also had a diagnosis of autism [87]. This
same survey found that 33% of boys with a premutation
had developmental delays, which was significantly higher
than in a group of age-matched boys without a premuta-
tion (1.8%). A completely unbiased population of premu-
tation carriers that should be followed carefully are those
diagnosed by screening as newborns; three studies are
currently in progress in the USA.
Studies of neuropsychological deficits in premutation
carriers during adulthood have been complicated because
of the subclinical CNS changes that can occur related to
the development of FXTAS [109-111]. Studies have
detected deficits in executive function in a subgroup of
males with a premutation, but not in the corresponding
group of females [112-117]. In contrast to these four
reports, Hunter et al. [118] found no neuropsychological
deficits in 54 men with a premutation who were aged
under 50 years, although the Behavioral Dyscontrol Scale
(BDS) [113,119], which was found to be most sensitive to
executive dysfunction in older male carriers [112], was
not used. Clearly, recruitment bias is likely to affect adult
Figure 3 Potential mechanisms of FMR1 mRNA toxicity. Although numerous studies point to RNA toxicity as the underlying pathogenic
trigger in fragile X-associated tremor ataxia syndrome (FXTAS), the specific mechanism for such toxicity is not known. Possibilities include (1)
sequestration of one or more proteins that bind to the RNA, thus attenuating their other cell functions; (2) protein activation upon binding to
the CGG-repeat RNA, leading to dysregulation of one or more signaling cascades; and (3) various co-transcriptional process, such as R-loop
formation, that lead to DNA damage/repair signaling and consequent cellular dysregulation.
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emotional assessments. In contrast to the neuropsycholo-
gical testing, standardized emotional assessments have
demonstrated problems with anxiety and/or depression
in both males and females with a premutation, both with
and without FXTAS, compared with controls at multiple
centers [22,120-124]
An emerging phenotype includes the finding of
autoimmune problems in a subgroup of women with a
premutation. These problems include fibromyalgia,
hypothyroidism and multiple sclerosis, and they can
occur in women with a premutation both with and
without FXTAS [24,125-127]. Hunter et al. [82] found
that women with irregular cycles reported higher rates
of thyroid disease in addition to depression/anxiety.
The molecular process leading to the autoimmune pro-
blems are unknown, although they are most likely
related to the RNA toxicity. Predisposing factors lead-
ing to autoimmune disease in some females are likely
to be genetic, because in our clinical experience, they
cluster in families. Because of concern about the
genetic factors that underlie both autoimmune disease
and autism, we studied whether there is an increase in
ASD with FXS in the children of female carriers who
have autoimmune disease, compared with carriers who
do not have autoimmune disease [128]. The odds ratio
(OR) for ASD was 1.27 (P = 0.51) which was not
significant; however, the ORs for seizures and tics
in the offspring were 3.81 (P = 0.031) and 2.94
(P = 0.019) respectively. These results raise the possibi-
lity that there are intergenerational autoimmune
factors or perhaps auto-antibodies that affect the pre-
valence of seizures and tics in the offspring of mothers
with a premutation and autoimmune disease [128].
FMRP function throughout life leading to
targeted treatments for FXS
FMRP is an mRNA-binding protein that is important for
mRNA transport, mRNA stabilization and translation of
mRNA into protein at the synapse [129-131]. FMRP is
also a factor in the regulation of adult neurogenesis, so
in the absence of FMRP there is dysregulation of glyco-
gen synthase kinase (GSK)3b, reduced b-catenin and
defective Wnt signaling. These alterations lead to down-
regulation of neurogenin 1, which is an early initiator of
neuronal differentiation and an inhibitor of astrocyte
differentiation [132]. Therefore, FMRP is important
throughout life and there is a high incidence of motor
problems, including Parkinson disease (PD), with aging
in those with FXS [133]. In addition, in neuropathologic
studies, there is evidence of migration problems in the
hippocampus and in the cerebellum in those with FXS
(Greco et al,. unpublished data), which are similar to
those reported in individuals with autism [134]. These
problems may be related to dysregulation of Wnt signal-
ing in both FXS and autism.
Perhaps the most important change in protein expres-
sion in the absence of FMRP is the excess basal transla-
tion of proteins involved in the metabotropic glutamate
receptor (mGluR) 5 receptor pathway [135]. Bear and
colleagues have proposed the mGluR theory of FX, sug-
gesting that the deficits associated with FXS are related
to upregulation of the downstream effectors of the
mGluR5 pathway, leading to enhanced long-term
depression (LTD), and that treatment with an mGluR5
antagonist could be a targeted treatment for FXS
[135,136]. Both FMRP and mGluRs play important roles
in synaptogenesis and synaptic plasticity, and in the
absence of FMRP there are long, thin and immature
dendritic spines in both human and animal models of
FXS [137-142]. There are also enhanced, abnormal epi-
leptiform discharges consistent with an enhanced rate of
clinical seizures in FXS [143,144].
Support for the ‘mGluR theory’ has been shown by
generating FMR1 mutant mice with a 50% reduction in
mGluR5 expression [145]. The mGluR5 deficiency
rescued most of the KO mouse abnormalities including
altered ocular dominance plasticity, increased density of
dendritic spines on cortical pyramidal neurons,
increased basal protein synthesis in the hippocampus,
exaggerated inhibitory avoidance extinction, audiogenic
seizures and accelerated body growth. However, macro-
orchidism was not rescued. This work is supportive of
the proposal by Bear et al. [146]that excessive mGluR5
signaling is responsible for the psychiatric and neurolo-
gical symptoms of FXS, including cognitive deficits,
seizures, anxiety, perseverative movements and social
deficits.
Use of mGluR5 antagonists in animal models of FXS
further supports the mGluR theory. MPEP (2-methyl-6-
phenylethynyl pyridine hydrochloride) is a potent, highly
selective antagonist of mGluR5 receptors [147]. In vitro,
both MPEP and fenobam, another mGluR5 antagonist,
were able to rescue hippocampal dendritic abnormalities
in the KO mice [148,149]. MPEP has reversed audio-
genic seizures, epileptiform discharges, open field hyper-
activity and the defect in prepulse inhibition (PPI) of the
s t a r t l er e s p o n s ei nK Om i c e[ 1 4 8 - 1 5 0 ] .W h e nM P E P
and lithium, a partial mGluR5 antagonist that also
blocks GSK3b, were given to dfmr1 loss of function
Drosophila mutants, the flies had restored normal court-
ship behavior, memory and brain structural abnormal-
ities through the reduction of mGluR activity [151].
MPEP is toxic to humans, so other mGluR5 antagonists
including fenobam have been studied in FXS [152,153].
Fenobam was found to be safe in a single dose trial in
12 adults with FXS. There were improvements in hyper-
activity and anxiety, and 50% showed at least a 20%
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tional mGluR5 antagonists undergoing trials in adults
with FXS at multiple centers [153].
Other mechanisms to downregulate glutamate release
and modulate mGluR overactivity have been investigated.
g Aminobutyric acid (GABA)B receptor agonists, such as
baclofen, inhibit both presynaptic release of glutamate
and postsynaptic transmission and/or intracellular signal-
ing downstream from mGluR5 [154-156]. Baclofen has
been shown to be efficacious in treating hyperactivity
[157], marble burying (Seaside Therapeutics, unpublished
data) and audiogenic seizure phenotypes in FX KO mice
[158]. A double-blind, placebo-controlled, crossover trial
of arbaclofen, the right sided isomer of baclofen that is
significantly more potent than regular baclofen as a
GABA agent, has just been completed at multiple cen-
ters,and involved over 60 individuals with FXS (aged 6
years and older). The preliminary safety and efficacy
results are positive, with improvement in the Clinical
Global Impression Improvement scale in those with the
most severe baseline ratings [159]. There are also preli-
minary studies that are taking place involving individuals
with autism without FXS, and these studies have also
produced preliminary positive results. Therefore, further
studies on both FXS and autism are set to take place.
The GABAergic system is also dysregulated in FXS,
and GABA agents are important to consider for targeted
treatment studies in FXS. GABA is a major inhibitory
neurotransmitter receptor in the brain, which is impor-
tant in anxiety, depression, epilepsy, insomnia, and learn-
ing and memory [160]. GABA-mediated inhibition is
important for terminating ictal discharges and the spread
of hyperexcitability, which can lead to seizures [161].
There are two main subtypes of GABA receptors:
GABAA and GABAB. The main difference between
them is that the first is a ligand gated Cl
- channel that
gives fast inhibition, whereas the latter is a G-protein
coupled receptor which gives slower and more pro-
longed inhibitory signals [162,163]. The metabotropic
GABAB receptor can either be presynaptic and inhibit
the release of neurotransmitters through downregulation
of high-voltage activated Ca
2+-channels; or, when post-
synaptic, decrease neuronal excitability through its influ-
ence on K
+ channels. Thus, GABAB agonists such as
arbaclofen mediate their downregulating effects on
either side of the synapse. The ionotropic GABAA
receptor is usually localized postsynaptically, and their
activation leads to opening of Cl
- channels and hyperpo-
larization of the membrane potential, thus making it dif-
ficult for excitatory neurotransmitters such as glutamate
to generate an action potential. GABAA receptors are
more abundant than GABAB receptors in mammalian
brain, and disorders such as epilepsy, sleep disorders
and anxiety are now being treated using drugs that act
on the GABAA receptor[164].
Direct binding between FMRP and the mRNA of the
delta subunit of the GABAA receptor has been shown
[165]. Reduced expression and dysfunction of several sub-
units of the GABAA receptor (a1, a3, a4; b1, b2; g1, g2
and δ) have been shown in FX animal models [166-168].
FMR1 Drosophila mutants destined to die from glutamate
toxicity were rescued after administering molecules
involved in the GABAergic pathway [166]. In addition,
abnormal male courtship behavior and mushroom body
abnormalities were rescued by GABA agents [166].
There is a profound reorganization of neocortical inhi-
bitory circuits of GABAergic intraneurons in the KO
mouse [164,167-173]. Recent evidence indicates that
deficits in GABA-mediated inhibition may underlie
many of the key symptoms in FXS, including the sei-
zures, anxiety and autistic-like behaviors [167,169,173].
The neocortex in KO mice exhibits a marked reduction
i nt h ed e n s i t yo fG A B A e r g i ci n t e r n e u r o n st h a ts t a i n
with parvalbumin. Moreover, electrophysiological studies
in brain slices from these animals exhibit impaired
GABAA receptor-mediated inhibitory function [174]. In
addition to a gross reduction in GABA-mediated inhibi-
tion caused by the maldevelopment of inhibitory circuits
and the loss of GABAergic interneurons, there is also
evidence of altered GABAA receptor subunit expression
in the FX KO mouse [167]. In particular, there appears
to be a selective reduction in the expression of δ subu-
nits [167,168]. Global expression analysis by means of
the differential display in the FX mouse model revealed
consistent underexpression of only three genes, one of
which was the GABAA receptor subunit δ.A sG A B A A
receptors are the major inhibitory receptors in the brain,
and are specifically involved in processes that are dis-
turbed in FX, including neuronal excitability (leading to
enhanced seizure susceptibility), anxiety, sleep and
learning, enhancement of the function of GABAA recep-
tors may have major therapeutic benefits for FXS. Kooy
and colleagues [175] have demonstrated that use of the
GABAA agonist ganaxolone (3a-hydroxy-3b-methyl-5a-
pregnan-20-one) improved seizures in the KO mouse
model of FXS. Ganaxolone is a 3b-methylated synthetic
analog of the progesterone metabolite allopregnanolone,
which is itself a neuroactive steroid. Unlike progester-
one, neither allopregnanolone nor ganaxolone have
direct hormonal activity via progesterone receptor acti-
vation, and cannot cause hormonal side-effects. How-
ever, allopregnanolone and ganaxolone are powerful
positive allosteric modulators of GABAA receptors
[161]. Human trials indicate that ganaxolone is well
tolerated and that it may be efficacious in the treatment
of diverse forms of epilepsy in children and adults
Hagerman et al. Molecular Autism 2010, 1:12
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underway in children and adults with FXS.
Minocycline, a widely used antibiotic used to treat
acne and skin infections, is another promising drug that
may target core symptoms of FXS and autism. Minocy-
cline inhibits matrix metalloproteinase (MMP)-9 and
reduces inflammation in the central nervous system.
MMPs are enzymes involved in synaptic plasticity, and
are associated with immature dendritic spine morphol-
ogy [140,181]; MMP-9 is elevated in FXS. When mino-
cycline was administered to FMR1 KO mice, their
hippocampal neurons exhibited mature dendritic spines,
and behaviorally, they showed decreased anxiety and
improved exploration skills [140]. Off-label use of mino-
cycline to treat 50 individuals with FXS resulted in two-
thirds of families noticing positive improvements in
their child’s language, attention and/or behavioral
improvements while on the medication [182]. An open-
label trial is ongoing to investigate the effects of minocy-
cline on children with regressive autism at the National
Institute of Mental Health (NIMH). Paribello reported
beneficial effects on the CGI and the Aberrant Behavior
c h e c k l i s ti na no p e nt r i a lo fm i n o c y c l i n ei n v o l v i n g
patients with FXS who were aged 13 and older [183].
Currently, a double-blind, placebo-controlled clinical
trial is in progress at the Medical Investigation of Neu-
rodevelopmental Disorders (MIND) Institute for indivi-
duals with FXS who are aged 3.5 to 16 years
FXS has led the way for targeted treatments in neuro-
developmental disorders, and many of the treatments
guided by molecular abnormalities in FXS may also be
helpful for non-FX autism. The treatment trials will now
combine targeted treatments, which strengthen synaptic
connections, with enhanced educational and behavioral
interventions to further develop appropriate synaptic
connections in FXS. These targeted treatments combined
with educational interventions look promising for rever-
sing the intellectual and behavioral problems of FXS.
Because of the shared neurobiological and molecular
pathways, these interventions will hopefully also prove
helpful in a subset of patients with idiopathic autism
Conclusions
FX syndrome and autism are intertwined, because
FMRP regulates the translation of many messages that
affect synaptic plasticity and connectivity in the central
nervous system. The absence of FMRP also leads to
upregulation of mGluR5 pathways and downregulation
of GABAA pathways. Targeted treatments to reverse
these problems are currently being studied in patients
with FXS. Many of these targeted treatments may also
be helpful for ASD without FXS.
A premutation can also cause ASD, particularly in a sub-
set of young males, and the mechanism of involvement
relates to elevated mRNA levels causing dysregulation of
numerous proteins, early neuronal cell death in culture,
mitochondrial dysfunction and vulnerability to environ-
mental toxicity. Targeted treatments are currently being
developed for premutation involvement in early childhood,
and also for neurodegenerative problems including
FXTAS in aging individuals.
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